-
公开(公告)号：EP4377353A1
公开(公告)日：2024-06-05
申请号：EP22848721.1
申请日：2022-08-01
发明人： ZHANG, Yafeng , ZHU, Yanliang , ZHOU, Nannan , YANG, Shuai , WU, Shu
IPC分类号： C07K16/28 , C07K19/00 , A61K39/395 , A61P35/00
-
公开(公告)号：EP3743108A1
公开(公告)日：2020-12-02
申请号：EP19743231.3
申请日：2019-01-24
发明人： ZHAO, Tao , ZHANG, Huihui , YANG, Shuai , ZHANG, Yun , CHOU, Chuan-Chu , WU, Shu
IPC分类号： A61K39/395 , C07K16/28
-
公开(公告)号：EP3740507A1
公开(公告)日：2020-11-25
申请号：EP19738343.3
申请日：2019-01-15
发明人： ZHANG, Yafeng , WU, Shu , YANG, Shuai , CHOU, Chuan-Chu
IPC分类号： C07K16/28 , C12N5/10 , A61K39/395
-
公开(公告)号：EP3710480A1
公开(公告)日：2020-09-23
申请号：EP18877388.1
申请日：2018-11-13
发明人： ZHANG, Yafeng , WU, Shu , YANG, Shuai , CHOU, Chuan-Chu
-
公开(公告)号：EP3411079A1
公开(公告)日：2018-12-12
申请号：EP17746953.3
申请日：2017-01-26
发明人： FAN, Xiaohu , ZHANG, Fangliang , ZHUANG, Qiuchuan , WANG, Pingyan , YU, Jie , HE, Xian , WANG, Lin , HAO, Jiaying , YANG, Lei
CPC分类号： C12N5/0636 , A61K35/17 , A61K39/0011 , A61K2039/505 , A61K2039/507 , A61K2039/5156 , A61K2039/5158 , A61K2039/572 , C07K16/00 , C07K16/2818 , C07K16/2863 , C07K16/32 , C07K2317/73 , C12N5/16 , C12N2501/48 , C12N2501/51 , C12N2510/02 , C12N2740/16043
摘要： Provided are pharmaceutical compositions comprising an engineered mammalian cell comprising a heterologous nucleic acid encoding an immunomodulator. Further provided are methods of treating cancer using the pharmaceutical composition either singly or in combination with other technologies, such as Chimeric Antigen Receptor (CAR) or recombinant T cell receptor (TCR) modified T cell immunotherapy.
-
公开(公告)号：EP4377354A1
公开(公告)日：2024-06-05
申请号：EP22848722.9
申请日：2022-08-01
发明人： ZHANG, Yafeng , ZHU, Yanliang , TANG, Wanbing , YANG, Shuai , WU, Shu
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2803 , C07K2317/56520130101 , A61P35/02 , C07K2317/62220130101 , C07K2317/2220130101 , C07K2317/3320130101 , C07K2317/9220130101 , C07K14/7051 , C07K2319/0320130101 , C07K2317/3120130101 , C07K16/2851 , A61K39/001111 , A61K39/4611 , A61K39/4631 , A61K39/464411 , A61K39/464429 , A61K2239/2920230501 , A61K39/464402 , C07K2319/0020130101 , C12N2740/1604320130101 , A61K2239/3820230501 , A61K2239/3120230501
-
公开(公告)号：EP3732202A1
公开(公告)日：2020-11-04
申请号：EP18894132.2
申请日：2018-12-28
发明人： ZHANG, Wang , WU, Shu , YANG, Shuai , PAN, Qi , CHOU, Chuan-Chu
-
公开(公告)号：EP3645574A1
公开(公告)日：2020-05-06
申请号：EP18823268.0
申请日：2018-06-27
发明人： FAN, Xiaohu , ZHUANG, Qiuchuan , YANG, Lei , WANG, Pingyan , LI, Qingyan
IPC分类号： C07K16/46 , C12N15/13 , A61K39/395 , A61P35/00
-
公开(公告)号：EP3564266A1
公开(公告)日：2019-11-06
申请号：EP17889368.1
申请日：2017-12-29
发明人： FAN, Xiaohu , ZHUANG, Qiuchuan , WANG, Pingyan , YANG, Lei , ZHENG, Xiujun , HAO, Jiaying , LIU, Shaobo
摘要： The present invention discloses a novel chimeric antigen receptor and use thereof. Said novel chimeric antigen receptor consists of a signal peptide, an antigen binding domain, a transmembrane region, and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane region. The present invention separates and purifies nucleic acid sequences of a plurality of chimeric antigen receptors, and provides a chimeric antigen receptor and a CAR-T cell which are specific for a CD19 malignant tumor antigen. In the malignant tumor killing test of hematological cell lines, the ability of immune cells to target and recognize tumor cells is significantly enhanced, and the killing activity against tumor cells is also enhanced.
-
公开(公告)号：EP3526258A1
公开(公告)日：2019-08-21
申请号：EP17859600.3
申请日：2017-10-10
发明人： ZHANG, Yafeng , WU, Shu , YANG, Shuai , CHOU, Chuan-Chu
IPC分类号： C07K16/28 , C07K16/46 , C12N15/13 , A61K39/395 , A61P35/00
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.019 秒)
